{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:21:27Z","timestamp":1788297687601,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"DOI":"10.7759\/cureus.104552","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:30:13Z","timestamp":1772472613000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis"],"prefix":"10.7759","author":[{"given":"Petro E","family":"Petrides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2021.57.1.3230207","article-title":"Givosiran to treat acute porphyria","volume":"57","author":"Honor A","year":"2021","unstructured":"Honor A, Rudnick SR, Bonkovsky HL. Givosiran to treat acute porphyria. Drugs Today (Barc). 2021, 57:47-59. 10.1358\/dot.2021.57.1.3230207","journal-title":"Drugs Today (Barc)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani M","year":"2020","unstructured":"Balwani M, Sardh E, Ventura P, et al.. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020, 382:2289-301. 10.1056\/NEJMoa1913147","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v68i1.1422","article-title":"An introduction to the fundamentals of randomized controlled trials in pharmacy research","volume":"68","author":"Houle S","year":"2015","unstructured":"Houle S. An introduction to the fundamentals of randomized controlled trials in pharmacy research. Can J Hosp Pharm. 2015, 68:28-32. 10.4212\/cjhp.v68i1.1422","journal-title":"Can J Hosp Pharm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15090","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study","volume":"42","author":"Ventura P","year":"2022","unstructured":"Ventura P, Bonkovsky HL, Gouya L, et al.. Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study. Liver Int. 2022, 42:161-72. 10.1111\/liv.15090","journal-title":"Liver Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04547-3","article-title":"Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?","volume":"100","author":"Petrides PE","year":"2021","unstructured":"Petrides PE, Klein M, Schuhmann E, et al.. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit?. Ann Hematol. 2021, 100:1685-93. 10.1007\/s00277-021-04547-3","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2022.2110469","article-title":"Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran","volume":"16","author":"Ventura P","year":"2022","unstructured":"Ventura P, Sardh E, Longo N, et al.. Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran. Expert Rev Gastroenterol Hepatol. 2022, 16:879-94. 10.1080\/17474124.2022.2110469","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1207","article-title":"GetReal: from efficacy in clinical trials to relative effectiveness in the real world","volume":"7","author":"Egger M","year":"2016","unstructured":"Egger M, Moons KG, Fletcher C. GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Res Synth Methods. 2016, 7:278-81. 10.1002\/jrsm.1207","journal-title":"Res Synth Methods"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.58","article-title":"Aggregating case reports: a way for the future of evidence-based health care?","volume":"2","author":"Jackson D","year":"2014","unstructured":"Jackson D, Daly J, Saltman DC. Aggregating case reports: a way for the future of evidence-based health care?. Clin Case Rep. 2014, 2:23-4. 10.1002\/ccr3.58","journal-title":"Clin Case Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05908-4","article-title":"MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients","volume":"103","author":"Jilg S","year":"2024","unstructured":"Jilg S, Schwaab J, Sockel K, et al.. MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients. Ann Hematol. 2024, 103:4065-77. 10.1007\/s00277-024-05908-4","journal-title":"Ann Hematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03831-7","article-title":"Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families","volume":"98","author":"Bronisch O","year":"2019","unstructured":"Bronisch O, Stauch T, Haverkamp T, Beykirch MK, Petrides PE. Acute porphyrias: a German monocentric study of the biochemical, molecular genetic, and clinical data of 62 families. Ann Hematol. 2019, 98:2683-91. 10.1007\/s00277-019-03831-7","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2022.01.002","article-title":"Givosiran in acute intermittent porphyria: a personalized medicine approach","volume":"135","author":"Poli A","year":"2022","unstructured":"Poli A, Schmitt C, Moulouel B, et al.. Givosiran in acute intermittent porphyria: a personalized medicine approach. Mol Genet Metab. 2022, 135:206-14. 10.1016\/j.ymgme.2022.01.002","journal-title":"Mol Genet Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.04.004","article-title":"Renal function decline with small interfering RNA silencing aminolevulinic acid synthase 1 (ALAS1)","volume":"6","author":"Lazareth H","year":"2021","unstructured":"Lazareth H, Poli A, Bignon Y, et al.. Renal function decline with small interfering RNA silencing aminolevulinic acid synthase 1 (ALAS1). Kidney Int Rep. 2021, 6:1904-11. 10.1016\/j.ekir.2021.04.004","journal-title":"Kidney Int Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117334","article-title":"Case report of a complicated neurologically manifesting acute porphyria treated successfully with givosiran","volume":"422","author":"Steinberg T","year":"2021","unstructured":"Steinberg T, Kilic M, Fuchs K, Hanyk K, Linker RA, Schlachetzki F, Neumann B. Case report of a complicated neurologically manifesting acute porphyria treated successfully with givosiran. J Neurol Sci. 2021, 422:117334. 10.1016\/j.jns.2021.117334","journal-title":"J Neurol Sci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202404_36055","article-title":"Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report","volume":"28","author":"Mazzoli M","year":"2024","unstructured":"Mazzoli M, Ricci A, Vaudano AE, et al.. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report. Eur Rev Med Pharmacol Sci. 2024, 28:3268-74. 10.26355\/eurrev_202404_36055","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107670","article-title":"Acute hepatic porphyrias: recommendations for diagnosis and management with real-world examples","volume":"140","author":"Moghe A","year":"2023","unstructured":"Moghe A, Dickey A, Erwin A, et al.. Acute hepatic porphyrias: recommendations for diagnosis and management with real-world examples. Mol Genet Metab. 2023, 140:107670. 10.1016\/j.ymgme.2023.107670","journal-title":"Mol Genet Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jmd2.12354","article-title":"Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-an ongoing clinical conundrum","volume":"64","author":"Ma CD","year":"2023","unstructured":"Ma CD, Faust D, Bonkovsky HL. Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-an ongoing clinical conundrum. JIMD Rep. 2023, 64:146-9. 10.1002\/jmd2.12354","journal-title":"JIMD Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3284-23","article-title":"Hereditary coproporphyria in which the patient\u2019s course improved after the discontinuation of givosiran","volume":"63","author":"Ozaki N","year":"2024","unstructured":"Ozaki N, Hayashi Y, Kiyota A. Hereditary coproporphyria in which the patient\u2019s course improved after the discontinuation of givosiran. Intern Med. 2024, 63:2961-4. 10.2169\/internalmedicine.3284-23","journal-title":"Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2022.100946","article-title":"Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria","volume":"34","author":"Ma CD","year":"2023","unstructured":"Ma CD, Faust D, Bonkovsky HL. Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria. Mol Genet Metab Rep. 2023, 34:100946. 10.1016\/j.ymgmr.2022.100946","journal-title":"Mol Genet Metab Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101111","article-title":"Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: a monocenter real-life evaluation","volume":"40","author":"Guida CC","year":"2024","unstructured":"Guida CC, Nardella M, Del Mar Ys Perez A, et al.. Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: a monocenter real-life evaluation. Mol Genet Metab Rep. 2024, 40:101111. 10.1016\/j.ymgmr.2024.101111","journal-title":"Mol Genet Metab Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2024.101076","article-title":"Preventing hyperhomocysteinemia using vitamin B(6) supplementation in givosiran-treated acute intermittent porphyria: highlights from a case report and brief literature review","volume":"39","author":"Redonnet-Vernhet I","year":"2024","unstructured":"Redonnet-Vernhet I, Merci\u00e9 P, Lebreton L, et al.. Preventing hyperhomocysteinemia using vitamin B(6) supplementation in givosiran-treated acute intermittent porphyria: highlights from a case report and brief literature review. Mol Genet Metab Rep. 2024, 39:101076. 10.1016\/j.ymgmr.2024.101076","journal-title":"Mol Genet Metab Rep"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2024.03.015","article-title":"Personalized dosage of givosiran in acute intermittent porphyria [Article in Spanish]","volume":"163","author":"Garrido Montes M","year":"2024","unstructured":"Garrido Montes M, Pertusa Mataix R, Garcia Morillo JS. Personalized dosage of givosiran in acute intermittent porphyria [Article in Spanish]. Med Clin (Barc). 2024, 163:260-1. 10.1016\/j.medcli.2024.03.015","journal-title":"Med Clin (Barc)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.867856","article-title":"Case report: lack of response to Givosiran in a case of ALAD porphyria","volume":"13","author":"Graff E","year":"2022","unstructured":"Graff E, Anderson KE, Levy C. Case report: lack of response to Givosiran in a case of ALAD porphyria. Front Genet. 2022, 13:867856. 10.3389\/fgene.2022.867856","journal-title":"Front Genet"},{"key":"ref23","article-title":"Givosiran for the treatment of pediatric acute intermittent porphyria","volume":"46","author":"Bujold KE","year":"2024","unstructured":"Bujold KE, Kasher N, McKiernan C. Givosiran for the treatment of pediatric acute intermittent porphyria. J Pediatr Hematol Oncol. 2024, 46:e524-7. 1097\/MPH.0000000000002941","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21586","article-title":"Hereditary coproporphyria minimcking Gullain-Barr\u00e9 syndrome after COVID-19 infection","volume":"14","author":"Upchurch M","year":"2022","unstructured":"Upchurch M, Donnelly JP, Deremiah E, Barthol C, Hafeez S, Anderson KE, Seifi A. Hereditary coproporphyria minimcking Gullain-Barr\u00e9 syndrome after COVID-19 infection. Cureus. 2022, 14:e21586. 10.7759\/cureus.21586","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-99526-3","article-title":"Efficacy and safety of givosiran in Japanese patients with acute hepatic porphyria: clinical findings from an expanded access study","volume":"15","author":"Ozaki N","year":"2025","unstructured":"Ozaki N, Goto Y, Fujii N, Oyama T, Frascello K, Camejo A, Adachi T. Efficacy and safety of givosiran in Japanese patients with acute hepatic porphyria: clinical findings from an expanded access study. Sci Rep. 2025, 15:15321. 10.1038\/s41598-025-99526-3","journal-title":"Sci Rep"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13226779","article-title":"German real-world experience of patients with diverse features of acute intermittent porphyria treated with givosiran","volume":"13","author":"Kubisch I","year":"2024","unstructured":"Kubisch I, Wohmann N, Wissniowski TT, et al.. German real-world experience of patients with diverse features of acute intermittent porphyria treated with givosiran. J Clin Med. 2024, 13:6779. 10.3390\/jcm13226779","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03284-w","article-title":"Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1\/2, 48-month open-label extension study","volume":"19","author":"Sardh E","year":"2024","unstructured":"Sardh E, Balwani M, Rees DC, Anderson KE, Jia G, Sweetser MT, Wang B. Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1\/2, 48-month open-label extension study. Orphanet J Rare Dis. 2024, 19:365. 10.1186\/s13023-024-03284-w","journal-title":"Orphanet J Rare Dis"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.64211","article-title":"Pancreatitis is an emerging rare complication of classic homocystinuria: a case series and literature review","volume":"200","author":"Aljaberi R","year":"2026","unstructured":"Aljaberi R, Romo L, Cohen RZ, et al.. Pancreatitis is an emerging rare complication of classic homocystinuria: a case series and literature review. Am J Med Genet A. 2026, 200:155-61. 10.1002\/ajmg.a.64211","journal-title":"Am J Med Genet A"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.06.013","article-title":"Efficacy and safety of givosiran for acute hepatic porphyria: final results of the randomized phase III ENVISION trial","volume":"79","author":"Kuter DJ","year":"2023","unstructured":"Kuter DJ, Bonkovsky HL, Monroy S, et al.. Efficacy and safety of givosiran for acute hepatic porphyria: final results of the randomized phase III ENVISION trial. J Hepatol. 2023, 79:1150-8. 10.1016\/j.jhep.2023.06.013","journal-title":"J Hepatol"},{"key":"ref30","unstructured":"GIVLAARI (givosiran) injection, for subcutaneous use. initial U.S. approval. (2019). Accessed: 21.8.2024: https:\/\/www.alnylam.com\/sites\/default\/files\/pdfs\/GIVLAARI-Prescribing-Information.pdf."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12612","article-title":"Key terms and definitions in acute porphyrias: results of an international Delphi consensus led by the European porphyria network","volume":"46","author":"Stein PE","year":"2023","unstructured":"Stein PE, Edel Y, Mansour R, Mustafa RA, Sandberg S. Key terms and definitions in acute porphyrias: results of an international Delphi consensus led by the European porphyria network. J Inherit Metab Dis. 2023, 46:662-74. 10.1002\/jimd.12612","journal-title":"J Inherit Metab Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12071618","article-title":"Therapy follows diagnosis: old and new approaches for the treatment of acute porphyrias, what we know and what we should know","volume":"12","author":"Petrides PE","year":"2022","unstructured":"Petrides PE. Therapy follows diagnosis: old and new approaches for the treatment of acute porphyrias, what we know and what we should know. Diagnostics (Basel). 2022, 12:1618. 10.3390\/diagnostics12071618","journal-title":"Diagnostics (Basel)"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70156","article-title":"A prospective, blinded study of symptom prevalence and specificity of porphyrin precursors in carriers of acute hepatic porphyria","volume":"45","author":"Merati M","year":"2025","unstructured":"Merati M, Jayakumar N, Kapoor Y, et al.. A prospective, blinded study of symptom prevalence and specificity of porphyrin precursors in carriers of acute hepatic porphyria. Liver Int. 2025, 45:e70156. 10.1111\/liv.70156","journal-title":"Liver Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2012-201367","article-title":"Urinary excretion of porphyrins, porphobilinogen and \u03b4-aminolaevulinic acid following an attack of acute intermittent porphyria","volume":"67","author":"Marsden JT","year":"2014","unstructured":"Marsden JT, Rees DC. Urinary excretion of porphyrins, porphobilinogen and \u03b4-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol. 2014, 67:60-5. 10.1136\/jclinpath-2012-201367","journal-title":"J Clin Pathol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111477","article-title":"Therapeutic potential of 5-aminolevulinic acid in metabolic disorders: current insights and future directions","volume":"27","author":"Kuryata O","year":"2024","unstructured":"Kuryata O, Akimov O, Riabushko M, et al.. Therapeutic potential of 5-aminolevulinic acid in metabolic disorders: current insights and future directions. iScience. 2024, 27:111477. 10.1016\/j.isci.2024.111477","journal-title":"iScience"},{"key":"ref36","unstructured":"Gliolan. (2024). Accessed. 21.8.2024: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gliolan-epar-product-information_en.pdf."},{"key":"ref37","unstructured":"5-ALA. (2024). Accessed. 21.8.2024: https:\/\/www.amazon.co.jp\/s?k=5-ALA+tablets&crid=2H3192OU46U99&sprefix=%2Caps%2C720&ref=nb_sb_noss."},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23705","article-title":"Sodium ferrous citrate and 5-aminolevulinic acid improve type 2 diabetes by maintaining muscle and mitochondrial health","volume":"31","author":"Kitamura N","year":"2023","unstructured":"Kitamura N, Zhang S, Morel JD, et al.. Sodium ferrous citrate and 5-aminolevulinic acid improve type 2 diabetes by maintaining muscle and mitochondrial health. Obesity (Silver Spring). 2023, 31:1038-49. 10.1002\/oby.23705","journal-title":"Obesity (Silver Spring)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jphotobiol.2022.112484","article-title":"Modulation and proteomic changes on the heme pathway following treatment with 5-aminolevulinic acid","volume":"233","author":"Sansaloni-Pastor S","year":"2022","unstructured":"Sansaloni-Pastor S, Varesio E, Lange N. Modulation and proteomic changes on the heme pathway following treatment with 5-aminolevulinic acid. J Photochem Photobiol B. 2022, 233:112484. 10.1016\/j.jphotobiol.2022.112484","journal-title":"J Photochem Photobiol B"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1992.tb01482.x","article-title":"Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms","volume":"22","author":"Mustajoki P","year":"1992","unstructured":"Mustajoki P, Timonen K, Gorchein A, Sepp\u00e4l\u00e4inen AM, Matikainen E, Tenhunen R. Sustained high plasma 5-aminolaevulinic acid concentration in a volunteer: no porphyric symptoms. Eur J Clin Invest. 1992, 22:407-11. 10.1111\/j.1365-2362.1992.tb01482.x","journal-title":"Eur J Clin Invest"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyx074","article-title":"Randomized, prospective double-blinded study comparing 3 different doses of 5-aminolevulinic acid for fluorescence-guided resections of malignant gliomas","volume":"81","author":"Stummer W","year":"2017","unstructured":"Stummer W, Stepp H, Wiestler OD, Pichlmeier U. Randomized, prospective double-blinded study comparing 3 different doses of 5-aminolevulinic acid for fluorescence-guided resections of malignant gliomas. Neurosurgery. 2017, 81:230-9. 10.1093\/neuros\/nyx074","journal-title":"Neurosurgery"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.052","article-title":"Diagnosis and management of acute pancreatitis","volume":"167","author":"Trikudanathan G","year":"2024","unstructured":"Trikudanathan G, Yazici C, Evans Phillips A, Forsmark CE. Diagnosis and management of acute pancreatitis. Gastroenterology. 2024, 167:673-88. 10.1053\/j.gastro.2024.02.052","journal-title":"Gastroenterology"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2012.01.004","article-title":"Gallbladder patterns in acute pancreatitis: an MRI study","volume":"19","author":"Ji YF","year":"2012","unstructured":"Ji YF, Zhang XM, Li XH, Jing ZL, Huang XH, Yang L, Zhai ZH. Gallbladder patterns in acute pancreatitis: an MRI study. Acad Radiol. 2012, 19:571-8. 10.1016\/j.acra.2012.01.004","journal-title":"Acad Radiol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144818","article-title":"ASGR1 and its enigmatic relative CLEC10A","volume":"21","author":"Hoober JK","year":"2020","unstructured":"Hoober JK. ASGR1 and its enigmatic relative CLEC10A. Int J Mol Sci. 2020, 21:4818. 10.3390\/ijms21144818","journal-title":"Int J Mol Sci"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2022.2075848","article-title":"Givosiran for the treatment of acute hepatic porphyria","volume":"15","author":"Ricci A","year":"2022","unstructured":"Ricci A, Ventura P. Givosiran for the treatment of acute hepatic porphyria. Expert Rev Clin Pharmacol. 2022, 15:383-93. 10.1080\/17512433.2022.2075848","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref46","unstructured":"Protein expression overview | The Human Protein Atlas. Accessed. 21.8.2024: https:\/\/www.proteinatlas.org\/ENSG00000141505-ASGR1\/tissue."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2508237122","article-title":"An extended network for regulation of heme homeostasis in cells","volume":"122","author":"Gallio AE","year":"2025","unstructured":"Gallio AE, Marson NA, Heesom KJ, et al.. An extended network for regulation of heme homeostasis in cells. Proc Natl Acad Sci U S A. 2025, 122:e2508237122. 10.1073\/pnas.2508237122","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9181","article-title":"RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer","volume":"7","author":"Zuo M","year":"2016","unstructured":"Zuo M, Rashid A, Wang Y, et al.. RNA sequencing-based analysis of gallbladder cancer reveals the importance of the liver X receptor and lipid metabolism in gallbladder cancer. Oncotarget. 2016, 7:35302-12. 10.18632\/oncotarget.9181","journal-title":"Oncotarget"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1186\/s40543-025-00512-1","article-title":"Bile proteomics for discovery of biomarkers to differentiate between gallbladder polyp and gallstone","volume":"16","author":"Kwon H","year":"2025","unstructured":"Kwon H, Kim YE, Chung H, et al.. Bile proteomics for discovery of biomarkers to differentiate between gallbladder polyp and gallstone. J Anal Sci Technol. 2025, 16:41. 10.1186\/s40543-025-00512-1","journal-title":"J Anal Sci Technol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1653452","article-title":"Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system","volume":"12","author":"Xiao X","year":"2025","unstructured":"Xiao X, Nie Y, Leng Y. Asialoglycoprotein receptor 1: a multifaceted receptor in the liver and cardiovascular system. Front Med (Lausanne). 2025, 12:1653452. 10.3389\/fmed.2025.1653452","journal-title":"Front Med (Lausanne)"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v16.i4.1130","article-title":"Burden of gallstone disease in the United States population: prepandemic rates and trends","volume":"16","author":"Unalp-Arida A","year":"2024","unstructured":"Unalp-Arida A, Ruhl CE. Burden of gallstone disease in the United States population: prepandemic rates and trends. World J Gastrointest Surg. 2024, 16:1130-48. 10.4240\/wjgs.v16.i4.1130","journal-title":"World J Gastrointest Surg"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3140","article-title":"Gall bladder: the metabolic orchestrator","volume":"35","author":"Qi L","year":"2019","unstructured":"Qi L, Tian Y, Chen Y. Gall bladder: the metabolic orchestrator. Diabetes Metab Res Rev. 2019, 35:e3140. 10.1002\/dmrr.3140","journal-title":"Diabetes Metab Res Rev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.10.005","article-title":"Linking liver metabolic and vascular disease via bile acid signaling","volume":"28","author":"Fiorucci S","year":"2022","unstructured":"Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med. 2022, 28:51-66. 10.1016\/j.molmed.2021.10.005","journal-title":"Trends Mol Med"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000213","article-title":"Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes","volume":"7","author":"Dean AE","year":"2023","unstructured":"Dean AE, Jungwirth E, Panzitt K, Wagner M, Anakk S. Hepatic farnesoid X receptor is necessary to facilitate ductular reaction and expression of heme biosynthetic genes. Hepatol Commun. 2023, 7:10. 10.1097\/HC9.0000000000000213","journal-title":"Hepatol Commun"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21879","article-title":"Regulation of human liver delta-aminolevulinic acid synthase by bile acids","volume":"46","author":"Peyer AK","year":"2007","unstructured":"Peyer AK, Jung D, Beer M, et al.. Regulation of human liver delta-aminolevulinic acid synthase by bile acids. Hepatology. 2007, 46:1960-70. 10.1002\/hep.21879","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278(86)80496-2","article-title":"Chenodeoxycholic acid therapy in erythrohepatic protoporphyria","volume":"3","author":"Van Hattum J","year":"1986","unstructured":"Van Hattum J, Baart de la Faille H, Van den Berg JW, Edixhoven-Bosdijk A, Wilson JH. Chenodeoxycholic acid therapy in erythrohepatic protoporphyria. J Hepatol. 1986, 3:407-12. 10.1016\/s0168-8278(86)80496-2","journal-title":"J Hepatol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2597","article-title":"Givosiran likely inhibits cytochrome P450 more substantially than reported","volume":"112","author":"Bins S","year":"2022","unstructured":"Bins S, Sardh E, Langendonk JG. Givosiran likely inhibits cytochrome P450 more substantially than reported. Clin Pharmacol Ther. 2022, 112:24. 10.1002\/cpt.2597","journal-title":"Clin Pharmacol Ther"},{"key":"ref58","unstructured":"Conundrum. Accessed. 21.8.2024: https:\/\/www.dictionary.com\/e\/word-of-the-day\/conundrum-2022-02-11\/."},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2024-ICPP.2","article-title":"Patient demographics and clinical characteristics at enrollment in ELEVATE, an international registry of acute hepatic porphyria","volume":"11","author":"Sardh E","year":"2024","unstructured":"Sardh E, Cassiman D, Gouya L, et al.. Patient demographics and clinical characteristics at enrollment in ELEVATE, an international registry of acute hepatic porphyria. BMJ Open Gastroenterol. 2024, 11:10.1136\/bmjgast-2024-ICPP.2","journal-title":"BMJ Open Gastroenterol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12809","article-title":"Nontargeted urine metabolomic analysis of acute intermittent porphyria reveals novel interactions between bile acids and heme metabolism: new promising biomarkers for the long-term management of patients","volume":"48","author":"Lefebvre T","year":"2025","unstructured":"Lefebvre T, Eguether T, Th\u00e9venot E, et al.. Nontargeted urine metabolomic analysis of acute intermittent porphyria reveals novel interactions between bile acids and heme metabolism: new promising biomarkers for the long-term management of patients. J Inherit Metab Dis. 2025, 48:e12809. 10.1002\/jimd.12809","journal-title":"J Inherit Metab Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/445919-real-world-experience-with-givosiran-in-acute-porphyrias-a-narrative-review-and-a-novel-hypothesis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:30:18Z","timestamp":1772472618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/445919-real-world-experience-with-givosiran-in-acute-porphyrias-a-narrative-review-and-a-novel-hypothesis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":60,"URL":"https:\/\/doi.org\/10.7759\/cureus.104552","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}